Literature DB >> 18978995

Ole Isacson: development of new therapies for Parkinson's disease (interview).

Ole Isacson1.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 18978995      PMCID： PMC2535843          DOI： 10.3791/189

Source DB:  PubMed          Journal:  J Vis Exp        ISSN： 1940-087X            Impact factor:   1.355


× No keyword cloud information.
  5 in total

1.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

2.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.

Authors:  Ivar Mendez; Rosario Sanchez-Pernaute; Oliver Cooper; Angel Viñuela; Daniela Ferrari; Lars Björklund; Alain Dagher; Ole Isacson
Journal:  Brain       Date:  2005-05-04       Impact factor: 13.501

3.  Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons.

Authors:  Oliver Cooper; Ole Isacson
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

Review 4.  The production and use of cells as therapeutic agents in neurodegenerative diseases.

Authors:  Ole Isacson
Journal:  Lancet Neurol       Date:  2003-07       Impact factor: 44.182

5.  Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease.

Authors:  Rosario Sánchez-Pernaute; Andrew Ferree; Oliver Cooper; Meixiang Yu; Anna-Liisa Brownell; Ole Isacson
Journal:  J Neuroinflammation       Date:  2004-05-17       Impact factor: 8.322
  5 in total
  1 in total

1.  Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test.

Authors:  Fabio S L da Conceição; Stacie Ngo-Abdalla; Jean-Christophe Houzel; Stevens K Rehen
Journal:  J Vis Exp       Date:  2010-01-15       Impact factor: 1.355
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.